| Patent Number |
Title Of Patent |
Date Issued |
| 7335657 |
Cytokine inhibitors |
February 26, 2008 |
| Disclosed are compounds of formula (I) ##STR00001## Where Ar.sub.1, X, Y, Q, W, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.y are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases |
| 7279475 |
Fluorinated di-aryl urea compounds |
October 9, 2007 |
| Disclosed are compounds of formula(I): ##STR00001## wherein R.sub.1, R.sub.2, W and X of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving in |
| 7211575 |
Methods of treating cytokine mediated diseases |
May 1, 2007 |
| Disclosed are methods of treating acute and chronic inflammation in the lung caused by inhalation of smoke, endometriosis, Behcet's disease, uveitis, ankylosing spondylitis, pancreatitis, cancer, Lyme disease, sepsis, chronic obstructive pulmonary disease, traumatic arthritis, conges |
| 7115644 |
Heterocyclic compounds |
October 3, 2006 |
| Disclosed are benzimidazolone compounds of formulas (I) & (II):wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and path |
| 7078419 |
Cytokine inhibitors |
July 18, 2006 |
| Disclosed are compounds of formula (I) ##STR00001## Where Ar.sub.1, X, Y, Q, W, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.y are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases |
| 6916814 |
Methods of treating cytokine mediated diseases |
July 12, 2005 |
| Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar.sub.1,Ar.sub.2,L,Q and X are described herein. ##STR1## |
| 6872726 |
Fluorinated di-aryl urea compounds |
March 29, 2005 |
| Disclosed are compounds of formula (I): ##STR1##wherein R.sub.1, R.sub.2, W and X of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflam |
| 6852717 |
Compounds useful as anti-inflammatory agents |
February 8, 2005 |
| Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds. |
| 6844435 |
Heterocyclic compounds useful as inhibitors of tyrosine kinases |
January 18, 2005 |
| Disclosed are novel compounds of formula (I): ##STR1##wherein Ar.sub.1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include a |
| 6770639 |
Heterocyclic compounds useful as inhibitors of tyrosine kinases |
August 3, 2004 |
| Disclosed are novel compounds of formula (I): ##STR1##wherein Ar.sub.1, R.sub.a, R.sub.4, R.sub.5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseas |
| 6765009 |
1,4-Disubstituted benzo-fused compounds |
July 20, 2004 |
| Disclosed are novel 1,4-disubstituted benzo-fused compounds wherein G, X, L, Q, n and Y are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed |
| 6660732 |
Compounds useful as anti-inflammatory agents |
December 9, 2003 |
| Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds. |
| 6506769 |
Heterocyclic compounds useful as inhibitors of tyrosine kinases |
January 14, 2003 |
| Disclosed are novel compounds of formula (I): ##STR1##wherein Ar.sub.1, R.sub.a, R.sub.4, R.sub.5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseas |
| 6489328 |
Heterocyclic compounds useful as inhibitors of tyrosine kinases |
December 3, 2002 |
| Disclosed are novel compounds of formula (I): ##STR1##wherein Ar.sub.1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include a |
| 6313095 |
Antiherpes tetrapeptide derivatives having a substituted aspartic acid side chain |
November 6, 2001 |
| Disclosed herein are tetrapeptide derivatives of the formula X--NH--CHR.sup.1 --C(W.sup.1)--NR.sup.2 --CH[CH.sub.2 C(O)--Y]--C(W.sup.2)--NH--CH[CR.sup.3 (R.sup.4)--COOH]--C(W.sup.3)--NH--CHR.sup.5 --Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R. |
| 6284768 |
Src family SH2 domain inhibitors |
September 4, 2001 |
| This invention relates to compounds of formula (I): ##STR1##wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands. |
| 6268365 |
Src family SH2 domain inhibitors |
July 31, 2001 |
| This invention relates to compounds of formula (1): ##STR1##wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands. |
| 6228881 |
Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
May 8, 2001 |
| Novel aromatic heterocyclic compounds inhibit cytokines production involved in immunoregulation and inflammation such as interleukin-1 and tumor necrosis factor production. The compounds are therefore useful in pharmaceutic compositions for treating diseases or pathological conditions |
| 6156784 |
Compounds useful as phosphotyrosine mimics |
December 5, 2000 |
| Disclosed are compositions containing compounds of the formula (I) below wherein A,B,C,G,Q and R are defined herein. The compounds are useful as phosphotyrosine mimics that, when incorporated into an appropriate molecular structure, inhibit the binding of tyrosine kinase-dependent re |
| 6080763 |
Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
June 27, 2000 |
| Novel aromatic heterocyclic compounds inhibit cytokines production involved in immunoregulation and inflammation such as interleukin-1 and tumor necrosis factor production. The compounds are therefore useful in pharmaceutic compositions for treating diseases or pathological conditions |
| 6054470 |
Src family SH2 domain inhibitors |
April 25, 2000 |
| This invention relates to compounds of formula (1): ##STR1## wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands. |
| 5846941 |
Isosteric antiherpes peptide derivatives II |
December 8, 1998 |
| Disclosed herein are peptidomimetic compounds of the formula A--B--D--CH.sub.2 CH{CH.sub.2 C(O)R.sup.1 }C(O)--NHCH{CR.sup.2 (R.sup.3)COOH}C(O)--E wherein A is a terminal group, for example an optionally substituted phenylalkanoyl, and B is a N-methyl amino acid residue; or A and B to |
| 5830864 |
Antiherpes peptide derivatives having a ureido n-terminus |
November 3, 1998 |
| Disclosed herein are peptide derivatives of the formulawherein A is a terminal group, for example, an alkylaminocarbonyl or a phenylalkylaminocarbonyl; B is an amino acid residue; R.sup.1 is alkyl, cycloalkyl or a disubsubstituted amino; R.sup.2 is hydrogen or alkyl and R.sup.3 is alkyl, |
| 5672586 |
Herpes ribonucleotide reductase inhibitors |
September 30, 1997 |
| Disclosed herein are compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or (1-4C) alkyl, R.sup.2 is (1-4C) alkyl or a therapeutically acceptable salt thereof. The compounds are useful for treating herpes infections. |
| 5574015 |
Isosteric antiherpes peptide derivatives |
November 12, 1996 |
| Disclosed herein are peptide derivatives of the formula A-B-D-CH.sub.2 CH{CH.sub.2 C(O)R.sup.1 }C(O)-NHCH{CR.sup.2 (R.sup.3)COOH}C(O)-E wherein A is a terminal group, for example an optionally substituted phenylalkanoyl, and B is a N-methyl amino acid residue; or A and B together form a |
| 5502036 |
Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain |
March 26, 1996 |
| Disclosed herein are pentapeptide derivatives of the formula X--NR.sup.1 --CH(R.sup.2)--C(W)--NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH[CH.sub.2 C(O)--Y]--C(W.sup.3)--NH--CR.sup.6 --[CR.sup.7 (R.sup.8)--COOH]--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a terminal gro |
| 5484771 |
Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus |
January 16, 1996 |
| Described herein are peptide derivatives of the formula R.sup.1 NH--CO--Q--C(O)--NR.sup.2 --CH[CH.sub.2 C(O)--Y]--C(O)--NH--CH[CR.sup.3 (R.sup.4)--COOH]--C(W)--NH--CHR.sup.5 --Z wherein R.sup.1 is an optionally substituted alkyl or optionally substituted phenylalkyl, R.sup.2 is hydro |
| 5476841 |
Inhibitors of herpes viral ribonucleotide reductase |
December 19, 1995 |
| Peptide derivatives are of the formula A--B--D--NHCH{CH.sub.2 C(O)R.sup.1 }C(O)--NHCH{CR.sup.2 (R.sup.3)--COOH}C(O)--E wherein A is a lower alkanoyl bearing two substituents, each substituent selected independently from phenyl or a monosubstituted phenyl wherein the monosubstituent is al |
